DoW Neurofibromatosis Exploration-Hypothesis Development Award
Dept. of Defense — CDMRP · Other Federal · HT942526NFRPEHDA
Source: Grants.gov · View original posting ↗
- AwardWhat a single award can be worth — the funder's published per-award amount or floor–ceiling range.
- $1.3M total
- DeadlineFinal application due date.
- Sep 22, 2026
- Letter of intentDue date for the letter of intent (a short pre-application some funders require or request before the full proposal).
- —
- MechanismNIH activity code — the grant type (R01 research project, R21 exploratory, K series career development, F series fellowship, …).
- —
- DurationMaximum project period for a single award.
- —
- Expected awardsHow many awards the funder anticipates making under this opportunity.
- 8
- Funding cycleHow often the program accepts applications (annual, multiple cycles per year, rolling, or one-time).
- Unknown
- Open dateWhen applications open (or opened).
- Jun 25, 2026
- Total fundingThe overall pool the funder expects to commit across ALL awards under this opportunity — not what one project receives.
- $1.3M total
- Clinical trialWhether proposed projects must, may, or must not include a clinical trial.
- Unspecified
Research areas
Auto-classified from the title and description (keyword-based) — may be imperfect.
Description
Summary: The fiscal year 2026 (FY26) Neurofibromatosis Research Program (NFRP) Exploration-Hypothesis Development Award (EHDA) supports the initial exploration of innovative, high-risk, high-gain, and potentially groundbreaking concepts in neurofibromatosis (NF) research. Studies supported by this award mechanism should lay the groundwork for future avenues of scientific investigation. The proposed research project should include a well-formulated, testable hypothesis based on strong scientific rationale and study design. Distinctive Features: • Innovation: The proposed research project should be innovative. Innovative research may introduce a novel paradigm, challenge existing paradigms, examine existing problems from novel perspectives, or exhibit other highly creative qualities. • Preliminary Data: Preliminary and/or published data is encouraged but not required.